

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert H. Getzenberg
Title: RENAL NUCLEAR MATRIX PROTEINS, POLYNUCLEOTIDE
SEQUENCES ENCODING THEM, AND THEIR USE
Prior Appl. No.: 09/050,991
Prior Appl. Filing Date: 03/31/1998
Examiner: Unassigned
Art Unit: Unassigned

PRELIMINARY AMENDMENT

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

Prior to examination of the above-identified application, Applicant respectfully requests that the following amendments be entered into the application:

In the Specification:

After the Application Title, please insert:

This is a Divisional Application of Application No. 09/050,991, filed March 31, 1998.

In the Claims:

Please delete claims 1-3, 16-17, 21 and 40-43 in accordance with 37 CFR §1.121, please substitute original claims 4-15, 18-20, 22-39 and 44-47 for the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Versions With Markings to Show Changes Made."

4. (Amended) A purified polynucleotide sequence encoding a nuclear matrix protein that is present in normal renal cells but absent in cancerous renal

cells, or that is absent in normal renal cells but present in cancerous renal cells, or a fragment thereof.

15. (Amended) An antibody which binds to the protein encoded by the nucleotide sequence of claim 4.

18. (Amended) A method for detecting a cell proliferative disorder in a subject, comprising contacting a cellular component from the subject with a reagent which binds to a cellular component associated with a cell proliferative disorder; wherein the cellular component is nucleic acid.

22. (Amended) The method of claim 18, wherein the reagent is a probe.

35. (Amended) A method of gene therapy, comprising introducing into the cells of a host subject an expression vector comprising the nucleotide sequence of claim 4.

44. (Amended) A kit useful for the detection of a cell-proliferative disorder, said kit comprising a probe for identifying the polynucleotide sequence of claim 4.


REMARKS

Entry of the foregoing amendments prior to examination is respectfully requested.

Respectfully submitted,

Date May 8, 2001

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

By 
Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

VERSIONS WITH MARKINGS TO SHOW CHANGES MADE

4. (Amended) A purified polynucleotide sequence encoding a [protein or fragment] nuclear matrix protein that is present in normal renal cells but absent in cancerous renal cells, or that is absent in normal renal cells but present in cancerous renal cells, or a fragment thereof.

15. (Amended) An antibody which binds to the protein encoded by the nucleotide sequence of claim [1] 4.

18. (Amended) A method for detecting a cell proliferative disorder in a subject, comprising contacting a cellular component from the subject with a reagent which binds to a cellular component associated with a cell proliferative disorder.

[The method of claim 17] wherein the cellular component is nucleic acid.

22. (Amended) The method of claim [16] 18, wherein the reagent is a probe.

35. (Amended) A method of gene therapy, comprising introducing into the cells of a host subject an expression vector comprising [a] the nucleotide sequence [encoding a protein] of claim [1] 4.

0950128-050801
T08050-82T05050

44. (Amended) A kit useful for the detection of a cell-proliferative disorder [associated with a protein of claim 1], said kit comprising a probe for identifying [a protein or fragment of claim 1 or a] the polynucleotide sequence [encoding a protein or fragment] of claim [1] 4.

0960128-050001